The median duration of systemic therapy was 11, 8.4, 7.3, and 0.8 years in the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−), HR+/HER2+, HR−/HER2+, and triple-negative breast cancer (TNBC) patients, respectively. The gene discussed is NR4A1; the disease is triple-negative breast carcinoma.